Pasithea Therapeutics -CW26KTTAWPreferred / convertible
13F holders, Q4 2025 (December 31)4holders −1
1new positions
2sold out
$0.01avg. 13F price*
At the end of Q4 2025, 4 institutions reported holding Pasithea Therapeutics -CW26 (KTTAW) in their 13F filings, down 1 from Q3 2025. 1 opened new positions and 2 sold out. The largest holders were Kepos Capital LP ($5K), Two Sigma Securities, LLC ($784) and Armistice Capital, LLC ($705).
- Company
- Pasithea Therapeutics -CW26
- CUSIP
- 70261F111
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $784 |
| Exits | 2 | $454 |
All 13F filers, Q3 2025 → Q4 2025: 55,579 shares bought and 29,777 shares sold, net +25,802 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Kepos Capital LP | — | No change | 334,600 | $5K |
| Two Sigma Securities, LLC | — | New | 55,579 | $784 |
| Armistice Capital, LLC | — | No change | 50,000 | $705 |
| Marex Group Ltd | — | No change | 25,000 | $345 |
"% of holder's portfolio" is KTTAW's weight in each manager's 13F, not the share of Pasithea Therapeutics -CW26 the manager owns.